Contact this trialFirst, we need to learn more about you.
Endothelin Receptor Antagonist
Atrasentan for IgA Nephropathy
Recruiting1 awardPhase 3
Huntsville, Alabama
This trial is testing if atrasentan is better than placebo at slowing down kidney function loss in people with IgA nephropathy.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.